Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:physicians:concerns [06.07.2019]
sallieq [Recorded success rates assessed 2013]
home:physicians:concerns [07.13.2019] (current)
sallieq [Concerns about immunopathology]
Line 7: Line 7:
 ===== Concerns about lack of clinical evidence ===== ===== Concerns about lack of clinical evidence =====
  
-  - **"​There are no well-controlled studies to support the use of the Marshall Protocol for a given indication."​** This statement is accurate. ​As of 2012, patients and physicians who choose ​to use and administer the MP do so based on the following evidence:+  - **"​There are no well-controlled studies to support the use of the Marshall Protocol for a given indication."​** This statement is accurate. ​In 2012, patients and physicians who chose to use and administer the MP did so based on the following evidence:
     * a [[home:​publications:​proal_molecular_2011|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//​     * a [[home:​publications:​proal_molecular_2011|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//​
     * a [[home:​publications:​mp2008_survey|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses     * a [[home:​publications:​mp2008_survey|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses
Line 17: Line 17:
  
 For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment: For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment:
-  * evidence ​for the efficacy ​of MP versus other available treatment options(({{pubmed>​long:​19050187}})) +  * alternative hypotheses and evidence of research ​(({{pubmed>​long: ​   ​15246025}})),​ (({{pubmed>​long:​16403216}})),​ (({{pubmed>​long:​23370376}})),​ (({{pubmed>​long:​18200565}}))  
-  * 2013 material ​on patient response, see section below +  * evidence for the efficacy of MP versus other available treatment in 2013 data on patient response, see section below 
   * patients'​ expressed preferences and values(({{pubmed>​long:​19050187}}))   * patients'​ expressed preferences and values(({{pubmed>​long:​19050187}}))
   * additional benefits of Olmesartan [[https://​mpkb.org/​home/​protocol/​olmesartan#​other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]   * additional benefits of Olmesartan [[https://​mpkb.org/​home/​protocol/​olmesartan#​other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]
Line 27: Line 27:
 <​html></​p></​div></​html>​ <​html></​p></​div></​html>​
  
-===== Recorded results assessed 2013  ​=====+==== Recorded results assessed 2013  ====
  
 <​blockquote>//​DJ posted// :- During the summer of 2013 I looked at 2,000 records of people using the Marshall Protocol.</​blockquote> ​ <​blockquote>//​DJ posted// :- During the summer of 2013 I looked at 2,000 records of people using the Marshall Protocol.</​blockquote> ​
Line 81: Line 81:
  
   - **"A temporary increase in symptoms or laboratory values means the treatment is not working."​** – \\ Immunopathology is an increase in one's present symptoms of Th1 inflammation or a return of previous Th1 inflammatory symptoms, that is caused by cytokines and endotoxins being released from dying bacteria. In some cases there may be a temporary experience of symptoms attributable to a previously unexperienced condition. Immunopathology is a necessary part of recovery. The amount of immunopathology a patient experiences on the Marshall Protocol (MP) is correlated with disease severity. Patients who are less sick will have comparatively less strong immunopathology. [[home:​protocol:​immunopathology|Read more →]]   - **"A temporary increase in symptoms or laboratory values means the treatment is not working."​** – \\ Immunopathology is an increase in one's present symptoms of Th1 inflammation or a return of previous Th1 inflammatory symptoms, that is caused by cytokines and endotoxins being released from dying bacteria. In some cases there may be a temporary experience of symptoms attributable to a previously unexperienced condition. Immunopathology is a necessary part of recovery. The amount of immunopathology a patient experiences on the Marshall Protocol (MP) is correlated with disease severity. Patients who are less sick will have comparatively less strong immunopathology. [[home:​protocol:​immunopathology|Read more →]]
 +
 +see also [[home:​protocol:​olmesartan:​safety#​recent_research|research into Enteropathy]] ​
  
 ===== Concerns about antibiotics===== ​ ===== Concerns about antibiotics===== ​
home/physicians/concerns.1559884136.txt.gz · Last modified: 06.07.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.